Stage 6 — Evaluate outcomes. Review the respiratory, infusion-site, and anticoagulation trends and answer the three outcome questions.
Trend
Choose your responses, then check the answer.
Explanation
Trend interpretation Persistent respirations of 8/min and end-tidal carbon dioxide 58 mm Hg after initial support justified protocol-directed titrated naloxone; improvement requires continued surveillance because naloxone can wear off before morphine. Stopping the painful 400 mEq/L peripheral potassium infusion and reassessing the site and potassium prevented further exposure. The 108-to-76-second aPTT trend after the case-specific nomogram action supports appropriate heparin management without bleeding. Patient and family teach-back and safety reporting address recurrence.
Respiratory outcome Evaluate respiratory rate and depth, responsiveness, ventilation data, and recurrence—not whether naloxone was avoided. Continued monitoring is needed after improvement because opioid effects may outlast reversal.
Potassium outcome A nonprogressing site and potassium 3.6 after stopping the infusion support the decision not to restart the same concentrated bag peripherally. The remaining dose is a new clinical decision, not an obligation to empty the bag.
Heparin outcome The current valid aPTT, bleeding assessment, actual nomogram action, and follow-up result form one loop. A result returning to the stated target without bleeding supports the response.
System outcome Teach-back, patient-only access, clinical documentation, safety reporting, concentrated-electrolyte route controls, and nomogram adherence are stronger than calling the episode harmless because the client improved.
Scenario (Stage 6 — Evaluate outcomes)The client improves after ventilation support and naloxone, the painful potassium infusion is discontinued, and the heparin result returns to target after protocol action.
Clinical judgment targetEvaluate sustained recovery and each medication-specific feedback loop without using avoidance of treatment as the success measure.
Renarcotization — Recurrence of opioid toxicity after an initial naloxone response when the opioid effect lasts longer than the antagonist, requiring continued assessment and sometimes repeat treatment.
Medication feedback loop — Assess, intervene according to the medication-specific order or protocol, remeasure the target outcome, evaluate harm, and hand off remaining risk.
Outcome-based safety evaluation — Judge success by sustained ventilation, prevention of tissue injury, safe coagulation control, understanding, and recurrence prevention rather than by uninterrupted infusion or absence of rescue medication.